Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome

Maria I. Vazquez-Roque, Ernest P. Bouras

Research output: Contribution to journalReview article

7 Scopus citations

Abstract

Chronic constipation (CC) and irritable bowel syndrome with constipation (IBS-C) are common gastrointestinal (GI) disorders. Current treatment options, either prescription or nonprescription medications, have limited efficacy in a subset of patients. There is significant demand for more efficacious medications for the treatment of CC and IBS-C. Linaclotide, a secretagogue, has a novel mechanism of action designed to treat patients with CC and IBS-C. It has a low oral bioavailability with negligible systemic side effects, and it acts locally in the intestinal lumen. In several clinical trials, in health and disease, linaclotide has demonstrated durable efficacy and safety in CC and IBS-C. Linaclotide received approval by the Federal Drug Administration in August 2012 to treat chronic idiopathic constipation and IBS-C.

Original languageEnglish (US)
Pages (from-to)203-211
Number of pages9
JournalAdvances in Therapy
Volume30
Issue number3
DOIs
StatePublished - Feb 25 2013

Keywords

  • Constipation
  • Gastroenterology
  • Guanylate cyclase C
  • Guanylin
  • Irritable bowel syndrome
  • Linaclotide
  • Uroguanylin

ASJC Scopus subject areas

  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome'. Together they form a unique fingerprint.

  • Cite this